Press release
Hemophilia Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Collaboration, and Other Developments
The hemophilia therapeutics pipeline is expected to grow in future due to rise in prevalence of genetic variation. Hemophilia which is symptomatized by excessive bleeding in brains, joints, nose and mouth. Some of the drivers for the growth of the hemophilia therapeutics pipeline include increasing incidence of hemophilia, less number of drugs present for treatment of hemophilia.Explore Report at: www.psmarketresearch.com/market-analysis/hemophilia-therapeutics-pipeline-analysis
Most of the large pharma companies are spending in research and development for treatment of haemophilia, which are in clinical trials. Pfizer, Inc. is developing a gene therapy in collaboration with Spark Therapeutics, Inc., through SPK-FIX program for treatment of haemophilia, as a potential onetime therapy. SPK-9001 is a bio-engineered adeno-associated virus (AAV) capsid expressing a codon-optimized, high-activity human factor IX variant, which was advanced using Spark's proprietary technology. Chugai Pharmaceutical is developing a compound in collaboration with F. Hoffmann-La Roche AG, Emicizumab, which is considered as a Breakthrough Therapy by the US Food and Drug Administration. LFB USA, Inc. is introducing a biological, wich is recombinant Coagulation FVIIa for the treatment of haemophilia. Coagulation FVIIa is currently in Phase III clinical development stage. Alnylam Pharmaceuticals Inc. is developing a drug for the treatment of haemophilia, ALN-AT3SC, which lowers the level of plasma antithrombin. ALN-AT3SC drug led to restoration of homeostasis in people with haemophilia. OPKO Biologics Ltd. Is developing a drug MOD-5014, whih is a long-acting recombinant FVIIa for the treatment of hemophiia A or B. Octapharma AG is developing a compound fr the treatment of haemophilia, Wilate, which is stable, double virus inactivated, stable, highly purified concentrate of freeze-dried, active von Willebrand factor (VWF) and FVIII. Wilate is currently in Phase III clinical development. Novo Nordisk A/S is estimating a homeostatic effect of turoctocog alfa pegol, which is currently in Phase III. Bayer AG is developing a compound BAY1093884. BAY1093884 is an anti-TFPI antibody which is currently in Phase I. Shire Plc is developing a compound SHP656, which is currently in Phase I clinical development.
Request for Table of Content at: www.psmarketresearch.com/market-analysis/hemophilia-therapeutics-pipeline-analysis
Some of the key players having a pipeline of hemophilia therapeutics include Shire Plc, Biogen, Pfizer Inc., Novo Nordisk A/S, CSL Behring, F. Hoffmann-La Roche Ltd., Bayer AG, Biotest AG, Kedrion Biopharma Inc., and Octapharma AG.
Browse Other Related Report at: www.psmarketresearch.com/industry-report/pharmaceuticals
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Contact:
Abhishek
Executive – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: www.psmarketresearch.com
347, 5th Ave. #1402
New York City, NY - 10016
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hemophilia Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Collaboration, and Other Developments here
News-ID: 524698 • Views: …
More Releases from P&S Market Research - Pharmaceuticals

Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Paten …
The study analyzed that the psoriasis therapeutics pipeline comprises approximately 150 drug candidates in different stages of development. Psoriasis is a chronic inflammatory disorder that causes red patches covered with white scales on the skin. It is characterized when a person’s immune system sends defective signals which results in skin cells to grow rapidly. The body does not shed these excess skin cells and pile up on the surface of…

Diabetic Foot Ulcer Therapeutics Pipeline Projects Immense Growth Ahead
The study analysed that the diabetic foot ulcer pipeline comprises of approximately 27 drug candidates in different stages of development.
Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/diabetic-foot-ulcers-therapeutics-pipeline-analysis
Diabetic foot ulcer is a serious complication of diabetes and can be defined as the ulceration in foot along with neuropathy or peripheral artery disease of the lower limb in diabetic patients. Diabetic foot ulcer is categorized into two types namely; neuropathic foot where…

Technological Advancements at Cellular and Molecular Level Strengthening the IgA …
The pipeline involves drug candidates that are being developed using specific targets such as a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS). More than three drug candidates are being developed using subcutaneous route of administration.
Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis
The study analyzed that the IgA nephropathy therapeutics pipeline comprises of 24 drug candidates in different stages of development. The report also includes epidemiology forecast for IgA Nephropathy for the…

Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF.
Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market
As per the findings of research, it…
More Releases for Phase
Three-Phase Hybrid Inverter Market Efficient and Reliable Power Conversion Solut …
Global Three-Phase Hybrid Inverter Market Overview:
The Three-Phase Hybrid Inverter market is a broad category that includes a wide range of products and services related to various industries. This market comprises companies that operate in areas such as consumer goods, technology, healthcare, and finance, among others.
In recent years, the Three-Phase Hybrid Inverter market has experienced significant growth, driven by factors such as increasing consumer demand, technological advancements, and globalization. This growth…
Clinical Trials by Phase (Phase I, Phase II, Phase III, Phase IV) Market Forecas …
A clinical trial is a research study, where a group of people is given a test or treatment. Clinical trials study the safety and efficacy of tests and treatments. If the test or treatment is safe and meets regulatory requirements, then it is approved as a standard of care.
Download Sample Copy at https://www.theinsightpartners.com/sample/TIPRE00006203/?utm_source=OpenPR&utm_medium=10379
Key Players Analysis:
IQVIA
Parexel International Corporation
Charles River Laboratories
ICON plc
SGS SA
Chiltern International Ltd
Syneos Health
PRA Health Sciences
Wuxi AppTec Inc
Pharmaceutical Product Development,…
Digital Phase Shifters Market
Digital Phase Shifters Market A recently identified vacuum in the literature about the creation of digital phase shifters for modern communication systems is attempted to be filled in the book Design of Digital Phase Shifters for Multipurpose Communication Systems. By significantly reducing RF power consumption and improving noise immunity, directed beams enhance the development of new-generation mobile communication systems. In this regard, digital phase shifters in particular, which are part…
COVID-19 - Pipeline Analysis 2020 for Global Market | Emphasis on Products cover …
COVID-19 (also known as Anderson COVID-19)?is a viral disease caused by RNA virus, SARS-CoV-2 or commonly known as corona virus. These viruses can cause respiratory, enteric, hepatic, and neurologic diseases. At the end of 2019, a new coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, China. It rapidly spread, resulting in an epidemic throughout China, followed by an increasing number of cases in other…
Power Metering Market Information by type (smart, digital, analog), by phase (si …
Power Metering Market Information by type (smart, digital, analog), by phase (single phase, three phase) by application (residential, commercial and industrial) and Region - Forecast to 2022
The report for Global Power Metering Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and…
HIV Vaccines Market Perceive Aggrandized Growth at a CAGR of 11.48% Till 2023 | …
HIV Vaccines Market Report Added on MarketResearchFuture.com with Overall Analysis. Key developments and Strategies Cover in this Report. The Market for Expected to Grow Globally Over the CAGR of 5 % During the Period 2018 to 2027 from USD 2,702.3 Billion in 2027.
HIV Vaccines Market - Segmentation
The global HIV vaccines market has been segmented on the basis of basis of antibiotics, type, and lastly, region.
Antibiotics have been segmented into dicloxacillin,…